2016 | 2015 | 2014 | 2013 | 2012 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006-2002 |
2016
January 2016: PPMI study protocol updated, allowing for continued participation for subjects in the Parkinson’s Disease and Health Control cohorts through 2018 and including an ancillary study to collect blood samples for the generation of induced pluripotent stem cells (iPSC) at select sites
2015
August 2015: PPMI team kicks off wide spread recruitment campaign to enroll genetic cohort subjects
February 2015: PPMI has now received 50 requests for biospecimens
March 2015: Launch of the expansion of the genetic cohort to study individuals with a GBA mutation
March 2015: Enrollment of prodromal cohort completed
2014
January 2014: First subjects enrolled in the PPMI genetic cohort and in the PPMI genetic registry
February 2014: Launch of the genetic cohort and registry to investigate the link between LRRK2 and SNCA genetic mutations and Parkinson’s
2014: PPMI expands to Israel, New York City, and France
2013
February 2013: Launch of prodromal cohort to investigate risk factors of PD: hypsomia, REM behavior sleep disorder (RBD), and the presence of a LRRK2 genetic mutation
April 2013: Enrollment of de novo PD, control, and SWEDD cohorts completed
July 2013: First subject enrolled in the Prodromal Cohort of PPMI
September 2013: PPMI Genetics Cohort Kick-Off meeting held in New York, NY
September 2013: First PPMI Study Update Call for participants
November 2013: Reached 100,000 downloads of the PPMI data
2013: PPMI expands to Greece, Spain, and Norway
2012
January 2012: 300 of the 600 subjects needed for PPMI are actively enrolled in the study
March 2012: PPMI expands to a third continent, Australia. One site is selected to participate in the study
Spring 2012: PPMI Steering Committee begins discussion of the addition of a new Pre-Motor PD cohort
Fall 2012: PPMI Steering Committee begins planning for the addition of a pre-motor cohort to the study
2011
March 2011: PPMI-info.org access to study data and specimens becomes available coinciding with 50 subjects having completed baseline visits
August 2011: : PPMI adds a third cohort: Subjects with SWEDD (Scans without Evidence of Dopamanergic Deficit)
September 2011: First Study Update Dinner for PPMI participants held in New Haven, Connecticut.
December 2011: First PPMI primary publication is published
2010
January 2010: Steering Committee meeting to finalize Protocol and discuss data flow and SOPs
March 2010: Investigators Meeting brings together members of the steering committee, study cores, clinical sites and MJFF; study protocols, tests and assessment details, recruitment and retention plans and outcomes are discussed
April 2010: First PPMI protocol goes into effect
June 2010: PPMI recruitment begins; first PPMI subject is enrolled
2009
June 2009: Protocol Task force is appointed; begins to define study design
August 2009: Steering Committee is formed
September 2009: Study Cores are selected
October 2009: Workshop to further refine core selection, define site selection process and set a timeline for study design and launch; verification study is conducted
2008
May 2008: Workshop to define study objectives, criteria for site selection and other study parameters
2007
February 2007: The Michael J. Fox Foundation (MJFF) Scientific Advisory Board holds a formal discussion on the need for a concerted biomarker effort
June 2007: Workshop to explore feasibility, required scientific expertise and MJFF’s role in a large-scale biomarkers study
October 2007: Workshop to further define the scientific cores that would be needed to support a large scale biomarkers study
2006-2002
MJFF sponsored three biomarker RFA’s and supported applications exploring clinical, imaging and biochemical biomarkers that would be useful in clinical trials
